July 30, 2008 -- Ondine Biopharma Corporation (Vancouver, BC, Canada) (TSX: OBP; AIM: OBP) says it has acquired an exclusive license for the human therapeutic use of a gold-nanoparticle photosensitizer from UCL Business PLC, the technology transfer company of University College London in London, UK. Ondine develops non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections.
"In vitro studies have shown that this advanced compound is one of the most potent photodisinfection agents ever developed," says Dr. Nicolas Loebel, Ondine's Chief Technology Officer. "The compound has proven highly efficacious in killing Methicillin/multi-drug Resistant Staphylococcus aureus, (MRSA), a prominent hospital-acquired pathogen. We intend to further develop this new agent for integration into our Photodisinfection System for various medical applications." Photodisinfection provides broad spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance.
Ondine is focused on developing and commercializing products utilizing its patented light-activated technology.